摘要
静脉血栓栓塞(VTE)是恶性肿瘤患者的常见并发症,可导致患者死亡率增加。VTE的发病机制与肿瘤细胞表达各种促凝物质引起的高凝状态和化学治疗导致的血管内皮损伤有关。在明确其发病机制的基础上给予针对性预防和治疗措施,对降低肿瘤患者的VTE发生率及死亡率具有重要意义。抗凝药物、溶栓药物以及祛聚治疗药物是目前临床应用较多的防治恶性肿瘤相关性VTE的药物。本文在查阅大量文献的基础上,对恶性肿瘤并发VTE的药物治疗和预防进展作一综述。
Venous thromboembolism （VTE） is one of the major complications in patients with malignant tumor. It could increase the mortality risk of malignant tumor patients. Hypercoagulability, stasis and vessel wall injury, which are associated with cancer or chemother- apy, are the mechanisms of VTE. Prophylaxis and treatment measures based on a clear understanding of the mechanisms of VTE are of great significance in decreasing the incidence of VTE and death rate of patients with cancer. Anticoagulants, thrombolytics and antiplatelet drugs are widely used in preventing and treating cancer-associated VTE. Based on a large number of related clinical reports and articles, this arti- cle is aimed at summarizing the progress of prophylaxis and treatment in patients with cancer.
出处
《肿瘤药学》
CAS
2017年第2期140-145,共6页
Anti-Tumor Pharmacy
关键词
静脉血栓
恶性肿瘤
抗凝治疗
Venous thromboembolism
Cancer
Anticoagulant therapy
